X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (86) 86
humans (84) 84
hematology (62) 62
multiple myeloma - drug therapy (62) 62
multiple myeloma (57) 57
aged (54) 54
bortezomib (46) 46
male (44) 44
female (43) 43
middle aged (42) 42
oncology (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
multiple myeloma - mortality (35) 35
thalidomide - administration & dosage (35) 35
therapy (33) 33
treatment outcome (33) 33
thalidomide (31) 31
melphalan - administration & dosage (29) 29
stem-cell transplantation (29) 29
dexamethasone (28) 28
lenalidomide (27) 27
chemotherapy (25) 25
disease-free survival (25) 25
survival (24) 24
abridged index medicus (23) 23
transplantation (23) 23
aged, 80 and over (22) 22
multiple myeloma - therapy (22) 22
elderly-patients (21) 21
prednisone - administration & dosage (21) 21
thalidomide - adverse effects (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
multiple myeloma - pathology (19) 19
adult (18) 18
thalidomide - analogs & derivatives (18) 18
care and treatment (17) 17
melphalan (17) 17
prednisone (16) 16
cancer (15) 15
dexamethasone - administration & dosage (14) 14
salvage therapy (14) 14
survival analysis (14) 14
thalidomide - therapeutic use (14) 14
antineoplastic agents - therapeutic use (13) 13
boronic acids - administration & dosage (13) 13
follow-up studies (13) 13
initial treatment (13) 13
peripheral neuropathy (13) 13
pyrazines - administration & dosage (13) 13
recurrence (13) 13
autologous transplantation (12) 12
drug therapy (12) 12
myeloma (12) 12
retrospective studies (12) 12
analysis (11) 11
bortezomib-melphalan-prednisone (11) 11
melphalan - adverse effects (11) 11
oral melphalan (11) 11
prognosis (11) 11
randomized controlled-trial (11) 11
cyclophosphamide (10) 10
hematology, oncology and palliative medicine (10) 10
kaplan-meier estimate (10) 10
multiple myeloma - diagnosis (10) 10
multiple-myeloma (10) 10
open-label (10) 10
patient outcomes (10) 10
prednisone plus thalidomide (10) 10
survival rate (10) 10
trial (10) 10
boronic acids - adverse effects (9) 9
carfilzomib (9) 9
combination (9) 9
diagnosed multiple-myeloma (9) 9
dose-response relationship, drug (9) 9
low-dose dexamethasone (9) 9
prednisone - adverse effects (9) 9
pyrazines - adverse effects (9) 9
stem cells (9) 9
transplantation, autologous (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
clinical trials as topic (8) 8
combined modality therapy (8) 8
dosage and administration (8) 8
lenalidomide plus dexamethasone (8) 8
neoplasm staging (8) 8
plus dexamethasone (8) 8
proteasome inhibitors (8) 8
research (8) 8
time factors (8) 8
antineoplastic agents, alkylating - administration & dosage (7) 7
clinical trials (7) 7
diagnosis (7) 7
disease progression (7) 7
efficacy (7) 7
hematopoietic stem cell transplantation (7) 7
maintenance (7) 7
plus thalidomide (7) 7
stem cell transplantation (7) 7
antineoplastic agents - adverse effects (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Haematologica, ISSN 0390-6078, 01/2015, Volume 100, Issue 10, pp. 1254 - 1266
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 367, Issue 9513, pp. 825 - 831
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2007, Volume 356, Issue 11, pp. 1110 - 1120
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 28, pp. 4459 - 4465
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 800 - 807
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2015, Volume 33, Issue 26, pp. 2863 - 2869
Journal Article
Haematologica, ISSN 0390-6078, 06/2013, Volume 98, Issue 6, pp. 980 - 987
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3279 - 3279
Journal Article
Journal Article